glp-1 ileus legal team in west virginia Weight Loss Drugs and Gastrointestinal Injuries: Patient Rights kentucky semaglutide digestive blockage lawyer

Aslam, M

Disclosures: Marie-Agns M'CALLUM: Nothing to Disclose, Quang Toan PHAM: Nothing to Disclose, Kristen Vieira-Lomasney: Nothing to Disclose, Eytan Haddad: Nothing to Disclose, Silvia Selleri: Abcellera Biologics: Employee, Massimiliano Paganelli: Morphocell Technologies: Executive role 1162 ASSOCIATION OF GLUCAGON-LIKE PEPTIDASE 1 RECEPTOR AGONIST WITH LIVER AND NON-LIVER COMPLICATIONS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS AND METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE Mindie Nguyen 1 Xianhua Mao 1 Xinrong Zhang 1 Rongtao Lai 2 Ka-Shing Cheung 3 Man-Fung Yuen 3 Ramsey Cheung 1 Wai-Kay Seto 3 , 1 Stanford University Medical Center, 2 Shanghai Jiao Tong University School of Medicine, 3 The University of Hong Kong Background: Although individuals with type 2 diabetes mellitus and metabolic dysfunction-associated steatotic liver disease (diabetic MASLD) face a higher lifelong risk of developing liver and non-liver morbidities, there so far are limited effective pharmacological strategies to reduce the disease burden in this population

MACE, major adverse cardiac events

SURPASS-CVOT will not compare tirzepatide to placebo as commonly done

Those are the type of information Im talking about that will help patients